Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
18.75
-0.61 (-3.18%)
Jan 22, 2026, 12:59 PM EST - Market open
Apollomics Revenue
Apollomics had revenue of $8.50M in the half year ending June 30, 2025, with 1,641.80% growth. This brings the company's revenue in the last twelve months to $6.93M, up 229.84% year-over-year. In the year 2024, Apollomics had annual revenue of $198.00K, down -75.88%.
Revenue (ttm)
$6.93M
Revenue Growth
+229.84%
P/S Ratio
3.08
Revenue / Employee
$533,077
Employees
13
Market Cap
40.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.00K | -623.00K | -75.88% |
| Dec 31, 2023 | 821.00K | 498.00K | 154.18% |
| Dec 31, 2022 | 323.00K | 321.00K | 16,050.00% |
| Dec 31, 2021 | 2.00K | -1.84M | -99.89% |
| Dec 31, 2020 | 1.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 31.80M |
| Veru Inc. | 16.89M |
| Exicure | 500.00K |
| Actinium Pharmaceuticals | 90.00K |
| INmune Bio | 50.00K |
APLM News
- 4 weeks ago - Apollomics Reports First Half 2025 Financial Results - GlobeNewsWire
- 2 months ago - Apollomics Announces Settlement of Cayman Litigation - GlobeNewsWire
- 2 months ago - Apollomics Announces Changes to its Board of Directors and Composition of Committees - GlobeNewsWire
- 3 months ago - Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation - GlobeNewsWire
- 3 months ago - Apollomics, Inc. Company Operational Continuity Update - GlobeNewsWire
- 10 months ago - Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - GlobeNewsWire
- 10 months ago - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewsWire
- 1 year ago - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire